Therapeutic manipulation of immune tolerance in allergic disease

Nature Reviews Drug Discovery

Volumn 8, Issue 8, 2009, Pages 645-660

  Akdis, Mübeccel ^a   Akdis, Cezmi A ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALLERGEN; AMB A 1 CPG OLIGODEOXYNUCLEOTIDE CONJUGATE; API M 1 API M 2 API M 3 FUSION PROTEIN; API M 1 API M 2 FUSION PROTEIN; BET V 1; CPG OLIGODEOXYNUCLEOTIDE; DACLIZUMAB; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN PEPTIDE 277; INTERLEUKIN 10; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 9; LEVOCETIRIZINE; MEPOLIZUMAB; MONOCLONAL ANTIBODY CD3; OMALIZUMAB; PEPTIDE VACCINE; PHOSPHORYL LIPID A; PLACEBO; PROTEIN DNAJ; RAPAMYCIN; RECOMBINANT ALLERGEN; RESLIZUMAB; SOLUBLE INTERLEUKIN 4 RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC RHINITIS; ANAPHYLAXIS; ANTIGEN PRESENTING CELL; ASTHMA; AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; BASOPHIL; CD4+ CD25+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MIGRATION; CELL SURVIVAL; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EFFECTOR CELL; EOSINOPHIL; GRAFT REJECTION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOTHERAPY; INNATE IMMUNITY; INSECT ALLERGY; INSULIN DEPENDENT DIABETES MELLITUS; IPEX SYNDROME; LYMPHOCYTE SUBPOPULATION; MAST CELL; NEUTROPHIL; NONHUMAN; POLLEN ALLERGY; PRIORITY JOURNAL; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; RHINOCONJUNCTIVITIS; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL;

ALLERGENS; ANIMALS; AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERSENSITIVITY; IMMUNE TOLERANCE; IMMUNOTHERAPY; T-LYMPHOCYTES;

EID: 68249141746     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2653     Document Type: Review

References (186)

1. Akdis, C. A. Mechanisms of allergic disease. Curr. Opin Immunol. 18, 718-726 (2006).
2. Noon, L. Prophylactic inoculation against hay fever. Lancet i, 1572-1573 (1911).
3. Akdis, M. Healthy immune response to allergens: T regulatory cells and more. Curr. Opin Immunol. 18, 738-744 (2006).
4. Larche, M., Akdis, C. A. & Valenta, R. Immunological mechanisms of allergen-specific immunotherapy. Nature. Rev. Immunol. 6, 761-771 (2006).
5. Durham, S. R. et al. Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. 341, 468-475 (1999).
6. Pajno, G. B., Barberio, G., De Luca, F., Morabito, L. & Parmiani, S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin. Exp. Allergy 31, 1392-1397 (2001).
7. Moller, C. et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J. Allergy Clin. Immunol. 109, 251-256 (2002).
8. Akdis, C. A. et al. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J. Clin. Invest. 98, 1676-1683 (1996).
9. Akdis, C. A., Blesken, T., Akdis, M., Wuthrich, B. & Blaser, K. Role of interleukin 10 in specific immunotherapy. J. Clin. Invest. 102 98-106 (1998).
10. Francis, J. N., Till, S. J. & Durham, S. R. Induction of IL-10 + CD4 + CD25 + T cells by grass pollen immunotherapy. J. Allergy Clin. Immunol. 111, 1255-1261 (2003).
11. Ling, E. M. et al. Relation of CD4 + CD25 + regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 363, 608-615 (2004).
12. Jutel, M. et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur. J. Immunol. 33, 1205-1214 (2003).
13. + T cells respond to superantigen and contribute to eosinophilia and IgE production in atopic dermatitis. J. Immunol. 163, 466-475 (1999).
14. Abernathy-Carver, K. J., Sampson, H. A., Picker, L. J. & Leung, D. Y. M. Milk-induced eczema is associated with the expansion of T cells expressing cutaneous lymphocyte antigen. J. Clin. Invest. 95 913-918 (1995).
15. Manz, R. A., Thiel, A. & Radbruch, A. Lifetime of plasma cells in the bone marrow. Nature 388, 133-134 (1997).
16. Gould, H. J. & Sutton, B. J. IgE in allergy and asthma today. Nature Rev. Immunol. 8, 205-217 (2008).
17. Mei, H. E. et al. Blood-borne human plasma cells in steady-state are derived from mucosal immune responses. Blood (2008).
18. Burgler, S. et al. Differentiation and functional analysis of human T(H)17 cells. J. Allergy Clin. Immunol. (2009).
19. Matsushita, S. & Higashi, T. Human Th17 cell clones and natural immune responses. Allergol. Int. 57, 135-140 (2008).
20. Dardalhon, V. et al. IL-4 inhibits TGF-beta-induced Foxp3 + T cells and, together with TGF-beta, generates IL-9 + IL-10 + Foxp3(-) effector T cells. Nature Immunol. 9, 1347-1355 (2008).
21. Veldhoen, M. et al. Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nature Immunol. 9, 1341-1346 (2008).
22. Prussin, C. Cytokine flow cytometry: Understanding cytokine biology at the single-cell level. J. Clin. Immunol. 17, 195-204 (1997).
23. Simon, H.-U. & Blaser, K. Inhibition of programmed eosinophil death: A key pathogenic event for eosinophilia. Immunol. Today 16, 53-55 (1995).
24. Whittaker, L. et al. Interleukin-13 mediates a fundamental pathway for airway epithelial mucus induced by CD4 T cells and interleukin-9. Am. J. Respir. Cell. Mol. Biol. 27, 593-602 (2002).
25. Sakaguchi, S., Yamaguchi, T., Nomura, T. & Ono, M. Regulatory T cells and immune tolerance. Cell 133, 775-787 (2008).
26. Chatila, T. A. Role of regulatory T cells in human diseases. J. Allergy Clin. Immunol. 116, 949-959; quiz 960 (2005).
27. Akdis, M., Blaser, K. & Akdis, C. A. T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J. Allergy Clin. Immunol. 116, 961-968 (2005).
28. Verhagen, J. et al. Absence of T-regulatory cell expression and function in atopic dermatitis skin. J. Allergy Clin. Immunol. 117, 176-183 (2006).
29. Deniz, G. et al. Regulatory NK cells suppress antigen-specific T cell responses. J. Immunol. 180, 850-857 (2008).
30. Zhou, J., Appleton, S. E., Stadnyk, A., Lee, T. D. & Nashan, B. A. CD8(+)gammadelta T regulatory cells mediate kidney allograft prolongation after oral exposure to alloantigen. Transpl. Int. (2008).
31. Akdis, M. et al. Immune responses in healthy and allergic Individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J. Exp. Med. 199, 1567-1575 (2004).
32. Meiler, F. et al. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J. Exp. Med. 205, 2887-2898 (2008).
33. 2. J. Immunol. 150, 3582-3591 (1993).
34. Platts-Mills, T., Vaughan, J., Squillace, S., Woodfolk, J. & Sporik, R. Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: A population-based cross-sectional study. Lancet 357, 752-756 (2001).
35. Reefer, A. J. et al. A role for IL-10-mediated HLA-DR7-restricted T cell-dependent events in development of the modified Th2 response to cat allergen. J. Immunol. 172, 2763-2772 (2004).
36. Steinbrink, K., Wolfl, M., Jonuleit, H., Knop, J. & Enk, A. H. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol. 159 4772-4780 (1997).
37. Wu, K. et al. Suppression of allergic inflammation by allergen-DNA-modified dendritic cells depends on the induction of Foxp3 + Regulatory T cells. Scand. J. Immunol. 67, 140-151 (2008).
38. Bellinghausen, I. et al. Inhibition of human allergic T-cell responses by IL-10-treated dendritic cells: Differences from hydrocortisone-treated dendritic cells. J. Allergy Clin. Immunol. 108, 242-249 (2001).
39. Kearley, J., Barker, J. E., Robinson, D. S. & Lloyd, C. M. Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4+CD25+ regulatory T cells is interleukin 10 dependent. J. Exp. Med. 202, 1539-1547 (2005).
40. Meiler, F., Klunker, S., Zimmermann, M., Akdis, C. A. & Akdis, M. Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors. Allergy 63, 1455-1463 (2008).
41. Gri, G. et al. CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity 29, 771-781 (2008).
42. Kearley, J., Robinson, D. S. & Lloyd, C. M. CD4+CD25+ regulatory T cells reverse established allergic airway inflammation and prevent airway remodeling. J. Allergy Clin. Immunol. 122, 617-624 e616 (2008).
43. Burchell, J. T., Wikstrom, M. E., Stumbles, P. A., Sly, P. D. & Turner, D. J. Attenuation of allergen-induced airway hyperresponsiveness is mediated by airway regulatory T cells. Am. J. Physiol. Lung Cell Mol. Physiol. 296, 307-319 (2009).
44. Hendrikx, T. K. et al. Monotherapy rapamycin allows an increase of CD4(+) CD25(bright+) FoxP3(+) T cells in renal recipients. Transpl. Int. 30 Apr 2009 (doi:10.1111/j.142-227.2009.00890.x).
45. Kremer, J. M. et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52, 2263-2271 (2005).
46. Utset, T. O. et al. Modified anti-CD3 therapy in psoriatic arthritis: A phase I/II clinical trial. J. Rheumatol 29, 1907-1913 (2002).
47. Isaacs, J. D. et al. Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. Arthritis Rheum. 44, 1998-2008 (2001).
48. Ehrenstein, M. R. et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J. Exp. Med. 200, 277-285 (2004).
49. O'Connor, R. A. & Anderton, S. M. Multi-faceted control of autoaggression: Foxp3+ regulatory T cells in murine models of organ-specific autoimmune disease. Cell Immunol. 251, 8-18 (2008).
50. Roncarolo, M. G. & Battaglia, M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nature Rev. Immunol. 7, 585-598 (2007).
51. Morse, M. A. et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112, 610-618 (2008).
52. Goforth, R. et al. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma. Cancer Immunol. Immunother. 58, 517-530 (2009).
53. Peek, E. J. et al. Interleukin-10-secreting "regulatory" T cells induced by glucocorticoids and beta2-agonists. Am. J. Respir. Cell Mol. Biol. 33, 105-111 (2005).
54. Karagiannidis, C. et al. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J. Allergy Clin. Immunol. 114, 1425-1433 (2004).
55. Akdis, M. & Akdis, C. A. Mechanisms of allergen-specific immunotherapy. J. Allergy Clin. Immunol. 119, 780-791 (2007).
56. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389, 737-742 (1997).
57. Akdis, C. A. et al. Inhibition of T helper 2-type responses, IgE production and eosinophilia by synthetic lipopeptides. Eur J. Immunol. 33, 2717-2726 (2003).
58. Izcue, A. et al. Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity 28, 559-570 (2008).
59. Chen, Y., Kuchroo, V. K., Inobe, J., Hafler, D. A. & Weiner, H. L. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis. Science 265, 1237-1240 (1994).
60. Fukaura, H. et al. Induction of circulating myelin basic protein and proteolipid protein- specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J. Clin. Invest. 98, 70-77 (1996).
61. Akdis, C. A. & Blaser, K. IL-10 induced anergy in peripheral T cell and reactivation by micro-environmental cytokines: Two key steps in specific immunotherapy. Faseb. J. 13, 603-609 (1999).
62. Varney, V. A. et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J. Clin. Invest. 92, 644-651 (1993).
63. Jutel, M. et al. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-g secretion in specific allergen stimulated T cell cultures. J. Immunol. 154, 4178-4194 (1995).
64. Durham, S. R. et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J. Allergy Clin. Immunol. 97, 1356-1365 (1996).
65. Nouri-Aria, K. T. et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J. Immunol. 172, 3252-3259 (2004).
66. Pilette, C. et al. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J. Immunol. 178, 4658-4666 (2007).
67. Radulovic, S., Jacobson, M. R., Durham, S. R. & Nouri-Aria, K. T. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J. Allergy Clin. Immunol. 121, 1467-1472 (2008).
68. Stavnezer, J., Guikema, J. E. & Schrader, C. E. Mechanism and regulation of class switch recombination. Annu Rev. Immunol. 26, 261-292 (2008).
69. Aalberse, R. C. & Platts-Mills, T. A. How do we avoid developing allergy: Modifications of the TH2 response from a B-cell perspective. J. Allergy Clin. Immunol. 113, 983-986 (2004).
70. Golden, D. B., Meyers, D. A., Kagey-Sobotka, A., Valentine, M. D. & Lichtenstein, L. M. Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy. J. Allergy Clin. Immunol. 69, 489-493 (1982).
71. Müller, U. R., Helbling, A. & Bischof, M. Predictive value of venom-specific IgE, IgG and IgG subclass antibodies in patients on immunotherapy with honey bee venom. Allergy 44, 412-418 (1989).
72. van der Giessen, M., Homan, W. L., van Kernbeek, G., Aalberse, R. C. & Dieges, P. H. Subclass typing of IgG antibodies formed by grass pollen-allergic patients during immunotherapy. Int. Arch. Allergy Appl. Immunol. 50, 625-640 (1976).
73. Jutel, M. et al. Allergen-specific immunotherapy with recombinant grass pollen allergens. J. Allergy Clin. Immunol. 116, 608-613 (2005).
74. Reisinger, J. et al. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J. Allergy Clin. Immunol. 116, 347-354 (2005).
75. Kehry, M. R. & Yamashita, L. C. Low-affinity IgE receptor (CD23) function on mouse B cells: Role in IgE-dependent antigen focusing. Proc. Natl Acad. Sci. USA 86, 7556-7560 (1989).
76. van Neerven, R. J. et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J. Immunol. 163 2944-2952 (1999).
77. Wachholz, P. A. & Durham, S. R. Mechanisms of immunotherapy: IgG revisited. Curr. Opin Allergy Clin. Immunol. 4, 313-318 (2004).
78. Till, S. J., Francis, J. N., Nouri-Aria, K. & Durham, S. R. Mechanisms of immunotherapy. J. Allergy Clin. Immunol. 113, 1025-1034 (2004).
79. Aalberse, R. C. & Schuurman, J. IgG4 breaking the rules. Immunology 105, 9-19 (2002).
80. van der Neut Kolfschoten, M. et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317 1554-1557 (2007).
81. Jakobsen, C. G., Bodtger, U., Kristensen, P., Poulsen, L. K. & Roggen, E. L. Isolation of high-affinity human IgE and IgG antibodies recognising Bet v 1 and Humicola lanuginosa lipase from combinatorial phage libraries. Mol. Immunol. 41, 941-953 (2004).
82. Jakobsen, C. G., Bodtger, U., Poulsen, L. K. & Roggen, E. L. Vaccination for birch pollen allergy: Comparison of the affinities of specific immunoglobulins E, G1 and G4 measured by surface plasmon resonance. Clin. Exp. Allergy 35, 193-198 (2005).
83. Klunker, S. et al. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J. Allergy Clin. Immunol. 120 688-695 (2007).
84. Radbruch, A. et al. Competence and competition: The challenge of becoming a long-lived plasma cell. Nature Rev. Immunol. 6, 741-750 (2006).
85. Pierkes, M. et al. Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-gamma production of T cells. J. Allergy Clin. Immunol. 103, 326-332 (1999).
86. Shim, Y. K., Kim, B. S., Cho, S. H., Min, K. U. & Hong, S. J. Allergen-specific conventional immunotherapy decreases immunoglobulin E-mediated basophil histamine releasability. Clin. Exp. Allergy 33, 52-57 (2003).
87. Marshall, J. S., Leal-Berumen, I., Nielsen, L., Glibetic, M. & Jordana, M. Interleukin (IL)-10 Inhibits long-term IL-6 production but not preformed mediator release from rat peritoneal mast cells. J. Clin. Invest. 97, 1122-1128 (1996).
88. Schandane, L. et al. B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10. J. Immunol. 152, 4368-4374 (1994).
89. Palaniyandi, S. S. et al. Inhibition of mast cells by interleukin-10 gene transfer contributes to protection against acute myocarditis in rats. Eur. J. Immunol. 34, 3508-3515 (2004).
90. Rak, S., Lowhagen, O. & Venge, P. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J. Allergy Clin. Immunol. 82, 470-480 (1988).
91. Hakansson, L., Heinrich, C., Rak, S. & Venge, P. Priming of eosinophil adhesion in patients with birch pollen allergy during pollen season: effect of immunotherapy. J. Allergy Clin. Immunol. 99, 551-562 (1997).
92. Rak, S., Hakanson, L. & Venge, P. Immunotherapy abrogates the generation of eosinophil and neutrophil chemotactic activity during pollen season. J. Allergy Clin. Immunol. 86, 706-713 (1990).
93. Lewkowicz, P., Lewkowicz, N., Sasiak, A. & Tchorzewski, H. Lipopolysaccharide-activated CD4+CD25+ T regulatory cells inhibit neutrophil function and promote their apoptosis and death. J. Immunol. 177, 7155-7163 (2006).
94. Ley, K., Smith, E. & Stark, M. A. IL-17A-producing neutrophil-regulatory Tn lymphocytes. Immunol. Res. 34, 229-242 (2006).
95. Akdis, C. A. Future of allergen-specific immunotherapy: Better understanding of the mechanisms, novel treatments, and long-term cure. Immuno. Allergy Clin. North Am. 26, xiii-xxii (2006).
96. Crameri, R. & Rhyner, C. Novel vaccines and adjuvants for allergen-specific immunotherapy. Curr. Opin Immunol. 18, 761-768 (2006).
97. Spangfort, M. D. & Larsen, J. N. Standardization of allergen-specific immunotherapy vaccines. Immunol. Allergy Clin. North Am. 26, 191-206, v-vi (2006).
98. Moverare, R., Elfman, L., Vesterinen, E., Metso, T. & Haahtela, T. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy 57, 423-430 (2002).
99. Passalacqua, G. et al. New insights in sublingual immunotherapy. Curr. Allergy Asthma Rep. 6, 407-412 (2006).
100. Wilson, D. R., Lima, M. T. & Durham, S. R. Sublingual immunotherapy for allergic rhinitis: Systematic review and meta-analysis. Allergy 60, 4-12 (2005).
101. Coyle, A. J. et al. Central role of immunoglobulin-E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: Inhibition by a non-anaphylactogenic anti-IgE antibody J. Exp. Med. 183, 1303-1308 (1996).
102. Akdis, C. A. & Blaser, K. Bypassing IgE and targeting T cells for specific immunotherapy of allergy. Trends Immunol. 22, 175-178 (2001).
103. Kahlert, H. et al. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy. Int. Arch. Allergy Immunol. 145, 193-206 (2008).
104. Pree, I. et al. Analysis of epitope-specific immune responses induced by vaccination with structurally folded and unfolded recombinant Bet v 1 allergen derivatives in man. J. Immunol. 179, 5309-5316 (2007).
105. Norman, P. et al. Treatment of cat allergy with T cell reactive peptides. Am. J. Repiratory Critical Care Med. 154, 1623-1628 (1996).
106. 2 induces specific T cell anergy in bee sting allergic patients. J. Allergy Clin. Immunol. 101, 747-754 (1998).
107. Marcotte, G. V. et al. Effects of peptide therapy on ex vivo T cell responses. J. Allergy Clin. Immunol. 101, 506-513 (1998).
108. von Garnier, C. et al. Allergen-derived long peptide immunotherapy down-regulates specific IgE response and protects from anaphylaxis. Eur. J. Immunol. 30, 1638-1645 (2000).
109. Haselden, B. M., Kay, A. B. & Larche, M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J. Exp. Med. 189, 1885-1894 (1999).
110. Oldfield, W. L., Larche, M. & Kay, A. B. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: A randomised controlled trial. Lancet 360, 47-53 (2002).
111. Larche, M. Immunoregulation by targeting T cells in the treatment of allergy and asthma. Curr. Opin Immunol. 18, 745-750 (2006).
112. Raz, I. et al. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): A randomised, double-blind, phase II trial. Lancet 358, 1749-1753 (2001).
113. Prakken, B. J. et al. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc. Natl Acad. Sci. USA 101, 4228-4233 (2004).
114. Kussebi, F. et al. A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. J. Allergy Clin. Immunol. 115, 323-329 (2005).
115. Karamloo, F. et al. Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epitopes. Eur. J. Immunol. 35, 3268-3276 (2005).
116. Niederberger, V. et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc. Natl Acad. Sci. USA 101, Suppl 2, 14677-14682 (2004).
117. Purohit, A. et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin. Exp. Allergy 38, 1514-1525 (2008).
118. Valenta, R. et al. The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin. Exp. Allergy 29, 896-904 (1999).
119. Valenta, R., Twaroch, T. & Swoboda, I. Component-resolved diagnosis to optimize allergen-specific immunotherapy in the Mediterranean area. J. Investig. Allergol. Clin. Immunol. 17, Suppl 1, 36-40 (2007).
120. Constantin, C. et al. Micro-arrayed wheat seed and grass pollen allergens for component-resolved diagnosis. Allergy 10 Feb 2009 [epub ahead of print].
121. Zhu, D., Kepley, C. L., Zhang, M., Zhang, K. & Saxon, A. A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation. Nature 8, 518-521 (2002).
122. Zhu, D. et al. A chimeric human-cat fusion protein blocks cat-induced allergy. Nature Med. 11, 446-449 (2005).
123. Rhyner, C., Kundig, T., Akdis, C. A. & Crameri, R. Targeting the MHC II presentation pathway in allergy vaccine development. Biochem. Soc. Trans. 35, 833-834 (2007).
124. Wang, R. F., Miyahara, Y. & Wang, H. Y. Toll-like receptors and immune regulation: Implications for cancer therapy. Oncogene 27, 181-189 (2008).
125. Alegre, M. L. et al. The multiple facets of toll-like receptors in transplantation biology. Transplantation 86, 1-9 (2008).
126. Lombardi, V. et al. Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route. Clin. Exp. Allergy 38, 1819-1829 (2008).
127. Johnson, A. G., Tomai, M., Solem, L., Beck, L. & Ribi, E. Characterization of a nontoxic monophosphoryl lipid A. Rev. Infect. Dis. 9, Suppl 5, 512-516 (1987).
128. Tapping, R. I., Akashi, S., Miyake, K., Godowski, P. J. & Tobias, P. S. Toll-like receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides. J. Immunol. 165, 5780-5787 (2000).
129. Baldridge, J. R. et al. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol. Ther. 4, 1129-1138 (2004).
130. Kawai, T. & Akira, S. TLR signaling. Semin. Immunol. 19, 24-32 (2007).
131. Casale, T. B., Kessler, J. & Romero, F. A. Safety of the intranasal toll-like receptor 4 agonist CRX-675 in allergic rhinitis. Ann. Allergy Asthma Immunol. 97, 454-456 (2006).
132. Patel, P. & Salapatek, A. M. Pollinex Quattro: A novel and well-tolerated, ultra short-course allergy vaccine. Expert Rev. Vaccines 5, 617-629 (2006).
133. Puggioni, F., Durham, S. R. & Francis, J. N. Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses. Allergy 60, 678-684 (2005).
134. Krieg, A. M. Therapeutic potential of Toll-like receptor 9 activation. Nature Rev. Drug Discov 5, 471-484 (2006).
135. Broide, D. et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness. J. Immunol. 161, 7054-7062 (1998).
136. Serebrisky, D. et al. CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma. J. Immunol. 165, 5906-5912 (2000).
137. Broide, D. H. et al. Systemic administration of immunostimulatory DNA sequences mediates reversible inhibition of Th2 responses in a mouse model of asthma. J. Clin. Immunol. 21, 175-182 (2001).
138. Horner, A. A. et al. Immunostimulatory DNA inhibits IL-4-dependent IgE synthesis by human B cells. J. Allergy Clin. Immunol. 108 417-423 (2001).
139. Baena-Cagnani, C., Rossi, G. A. & Canonica, G. W. Airway remodelling in children: When does it start? Curr. Opin Allergy Clin. Immunol. 7, 196-200 (2007).
140. Cho, J. Y. et al. Immunostimulatory DNA inhibits transforming growth factor-beta expression and airway remodeling. Am. J. Respir. Cell Mol. Biol. 30, 651-661 (2004).
141. Jain, V. V. et al. Mucosal immunotherapy with CpG oligodeoxynucleotides reverses a murine model of chronic asthma induced by repeated antigen exposure. Am. J. Physiol. Lung Cell Mol. Physiol. 285, 1137-1146 (2003).
142. Youn, C. J. et al. Immunostimulatory DNA reverses established allergen-induced airway remodeling. J. Immunol. 173, 7556-7564 (2004).
143. Simons, F. E., Shikishima, Y., Van Nest, G., Eiden, J. J. & HayGlass, K. T. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J. Allergy Clin. Immunol. 113, 1144-1151 (2004).
144. Creticos, P. S. et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N. Engl. J. Med. 355, 1445-1455 (2006).
145. Tulic, M. K. et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J. Allergy Clin. Immunol. 113, 235-241 (2004).
146. Casale, T. B. & Stokes, J. R. Immunomodulators for allergic respiratory disorders. J. Allergy Clin. Immunol. 121, 288-296 (2008).
147. Nelson, H. S. et al. Daclizumab improves asthma control in patients with refractory asthma. J. Allergy Clin. Immunol. 115 S134 (2005).
148. Vlad, G. et al. Anti-CD25 treatment and FOXP3- positive regulatory T cells in heart transplantation. Transpl. Immunol. 18, 13-21 (2007).
149. Flood-Page, P. T., Manzies-Gow, A. N., Kay, A. B. & Robinson, D. S. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respir. Crit. Care Med. 167, 199-204 (2003).
150. Kips, J. C. et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: A pilot study. Am. J. Respir. Crit. Care Med. 167, 1655-1659 (2003).
151. Flood-Page, P. et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J. Clin. Invest. 112, 1029-1036 (2003).
152. Phipps, S., Flood-Page, P., Menzies-Gow, A., Ong, Y. E. & Kay, A. B. Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin. J. Invest. Dermatol. 122, 1406-1412 (2004).
153. Andrews, A. L., Holloway, J. W., Holgate, S. T. & Davies, D. E. IL-4 receptor alpha is an important modulator of IL-4 and IL-13 receptor binding: Implications for the development of therapeutic targets. J. Immunol. 176, 7456-7461 (2006).
154. Borish, L. C. et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 160, 1816-1823 (1999).
155. Borish, L. C. et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy Clin. Immunol. 107 963-970 (2001).
156. Stein, M. L. et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J. Allergy Clin. Immunol. 118, 1312-1319 (2006).
157. Liu, Y. J. Thymic stromal lymphopoietin and OX40 ligand pathway in the initiation of dendritic cell-mediated allergic inflammation. J. Allergy Clin. Immunol. 120, 238-244 (2007).
158. Medoff, B. D., Thomas, S. Y. & Luster, A. D. T cell trafficking in allergic asthma: The ins and outs. Annu. Rev. Immunol. 26, 205-232 (2008).
159. Wang, Y. H. et al. IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. J. Exp. Med. 204, 1837-1847 (2007).
160. Kang, C. M. et al. Interleukin-25 and interleukin-13 production by alveolar macrophages in response to particles. Am. J. Respir. Cell Mol. Biol. 33, 290-296 (2005).
161. Dillon, S. R. et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nature Immunol. 5, 752-760 (2004).
162. Bilsborough, J. et al. IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J. Allergy Clin. Immunol. 117, 418-425 (2006).
163. Kakkar, R. & Lee, R. T. The IL-33/ST2 pathway: Therapeutic target and novel biomarker. Nature Rev. Drug Discov. 7, 827-840 (2008).
164. Tilg, H., Moschen, A. & Kaser, A. Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases. Expert Opin Biol. Ther. 7, 1051-1059 (2007).
165. Morjaria, J. B. et al. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: A double blind, randomised, placebo controlled trial. Thorax 63 584-591 (2008).
166. Berry, M. A. et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N. Engl. J. Med. 354, 697-708 (2006).
167. Wenzel, S. E. et al. A randomized, double-blind, placebo-controlled study of TNF-{alpha} blockade in severe persistent asthma. Am. J. Respir. Crit. Care Med. 179, 549-558 (2009).
168. Kuehr, J. et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J. Allergy Clin. Immunol. 109 274-280 (2002).
169. Casale, T. B. et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J. Allergy Clin. Immunol. 117, 134-140 (2006).
170. Jutel, M., Watanabe, T., Akdis, M., Blaser, K. & Akdis, C. A. Immune regulation by histamine. Curr. Opin Immunol. 14, 735-740 (2002).
171. Thurmond, R. L., Gelfand, E. W. & Dunford, P. J. The role of histamine H1 and H4 receptors in allergic inflammation: The search for new antihistamines. Nature Rev. Drug Discov. 7, 41-53 (2008).
172. Jutel, M. et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 413 420-425 (2001).
173. Muller, U. R. et al. Clinical and immunol.ogic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy. J. Allergy Clin. Immunol. 122, 1001-1007 (2008).
174. Allam, J. P. et al. Comparative analysis of nasal and oral mucosa dendritic cells. Allergy 61, 166-172 (2006).
175. Allam, J. P. et al. Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J. Allergy Clin. Immunol. 121, 368-374 e361 (2008).
176. Moingeon, P. et al. Immune mechanisms of allergenspecific sublingual immunotherapy. Allergy 61, 151-165 (2006).
177. Rossi, R. E., Monasterolo, G., Coco, G., Silvestro, L. & Operti, D. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy. Vaccine 25, 957-964 (2007).
178. Burastero, S. E. et al. Effect of sublingual immunotherapy with grass monomeric allergoid on allergen-specific T-cell proliferation and interleukin 10 production. Ann. Allergy Asthma Immunol. 100, 343-350 (2008).
179. Savolainen, J., Jacobsen, L. & Valovirta, E. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy 61, 1184-1190 (2006).
180. Bohle, B. et al. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J. Allergy Clin. Immunol. 120, 707-713 (2007).
181. Passalacqua, G. et al. Clinical and immunol.ogic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial. J. Allergy Clin. Immunol. 104, 964-968 (1999).
182. Lue, K. H. et al. Clinical and immunol.ogic effects of sublingual immunotherapy in asthmatic children sensitized to mites: A double-blind, randomized, placebo-controlled study. Pediatr. Allergy Immunol. 17, 408-415 (2006).
183. Alexander, C., Tarzi, M., Larche, M. & Kay, A. B. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in catallergic subjects. Allergy 60, 1269-1274 (2005).
184. Kundig, T. M. et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J. Allergy Clin. Immunol. 117, 1470-1476 (2006).
185. Johansen, P. et al. Direct intralymphatic injection of peptide vaccines enhances immunogenicity. Eur J. Immunol. 35, 568-574 (2005).
186. Senti, G. et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial. Proc. Natl Acad. Sci. USA 105, 17908-17912 (2008).